Gilead Sciences Inc (GILD)
Gilead - U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
Gilead - U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
PNC Releases Results of 2026 Dodd-Frank Company-Run Stress Test
Cantor Equity Partners I, Inc. Announces Postponement of Shareholder Meeting to 10:00 Am Eastern Time July 2, 2026
Jefferies Announces Second Quarter 2026 Financial Results
VICI Properties Inc. Completes Sale-Leaseback of Canadian Portfolio in Connection With Pure Casino Entertainment’s Acquisition of Gamehost
Worthington Steel Reports Fourth Quarter Fiscal 2026 Results
L3Harris Plans Arkansas Facility Expansion for PAC-3 Propulsion Production
Ryman Hospitality Properties, Inc. Addresses Recent Media Reports Regarding Opry Entertainment Group
Grand Canyon Education, Inc. Announces Second Quarter 2026 Earnings Release Date and Conference Call Details